Ballentine Partners, LLC Regeneron Pharmaceuticals, Inc. Transaction History

Ballentine Partners, LLC

$5.81 Billion
Q3 2024

A detailed history of Ballentine Partners, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Ballentine Partners, LLC holds 1,062 shares of REGN stock, worth $789,437. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,062

Previous 1,012 4.94%

Holding current value

$789,437

Previous $1.06 Million 4.99%

% of portfolio

0.02%

Previous 0.02%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 23, 2024	BUY	$1024.09 - $1201.76 $51,204 - $60,088	50 Added 4.94%	1,062 $1.12 Million
Q2 2024 Aug 06, 2024	SELL	$883.2 - $1071.19 $24,729 - $29,993	-28 Reduced 2.69%	1,012 $1.06 Million
Q1 2024 Apr 11, 2024	BUY	$902.69 - $993.35 $257,266 - $283,104	285 Added 37.75%	1,040 $1 Million
Q4 2023 Jan 23, 2024	SELL	$775.18 - $881.7 $186,818 - $212,489	-241 Reduced 24.2%	755 $663,000
Q3 2023 Oct 19, 2023	BUY	$692.45 - $844.37 $195,963 - $238,956	283 Added 39.69%	996 $819,000
Q2 2023 Jul 26, 2023	SELL	$700.03 - $830.35 $282,812 - $335,461	-404 Reduced 36.17%	713 $512,000
Q1 2023 Apr 27, 2023	BUY	$680.49 - $826.97 $232,727 - $282,823	342 Added 44.13%	1,117 $917,000
Q4 2022 Jan 27, 2023	BUY	$705.89 - $766.39 $136,942 - $148,679	194 Added 33.39%	775 $0
Q3 2022 Oct 26, 2022	BUY	$573.97 - $724.32 $133,735 - $168,766	233 Added 66.95%	581 $401,000
Q2 2022 Aug 09, 2022	SELL	$548.35 - $738.84 $16,450 - $22,165	-30 Reduced 7.94%	348 $206,000
Q1 2022 May 05, 2022	BUY	$595.12 - $698.43 $224,955 - $264,006	378 New	378 $264,000

Others Institutions Holding REGN

# of Institutions

1,531

Shares Held

84.1M

Call Options Held

1.22M

Put Options Held

1.51M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $79.7B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ballentine Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ballentine Partners, LLC with notifications on news.

Account

Ballentine Partners, LLC Regeneron Pharmaceuticals, Inc. Transaction History